# Vedana Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vedana-therapeutics

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.vedanatx.com
- Total disclosed funding: $46M
- Latest round: Series A (Jun 17, 2026)
- Investors on record: 3

## About

Based in the US, Vedana Therapeutics is a biotechnology company focused on developing innovative biologic medicines for migraine relief, targeting effective treatment pathways beyond traditional therapies.Vedana Therapeutics is engaged in the development of advanced biologic medicines for migraine relief. The company is headquartered in Seattle, US, and was founded by individuals with prior experience in the biotech sector. Vedana recently raised USD 46.00 mn in Series A funding on June 17, 2026, co-led by investors Canaan Partners and Westlake Village BioPartners, with participation from Alexandria Venture Investments. This funding is intended to support the development of their antibody programs targeting PACAP and CGRP pathways for migraine prevention.Vedana Therapeutics specializes in developing advanced biologic medicines aimed at providing migraine relief. Their core offerings include next-generation, long-acting therapeutics that enhance the efficacy of existing CGRP-targeted treatments and address PACAP and other CGRP-independent pathways. These products are tailored to target the underlying mechanisms of migraine, catering to healthcare providers, pharmacies, and patients seeking effective treatment options across key markets in North America and Europe.Vedana Therapeutics generates revenue through strategic partnerships and direct sales of its migraine therapies to healthcare providers and pharmacies. Their revenue model may include structured contracts that outline pricing and supply terms, potentially involving subscription models for ongoing therapeutic supply to clinics. Specific pricing details for their flagship products remain undisclosed, but the company focuses on building long-term relationships with healthcare professionals to ensure consistent access to its migraine treatments.In June 2026, Vedana Therapeutics raised USD 46 mn in Series A funding to support the development of their antibody programs targeting PACAP and CGRP pathways for migraine prevention. The company is planning to launch new products designed specifically for migraine relief while expanding into new geographical markets. This includes targeting additional regions in North America and Europe, with an aim to enhance availability for patients by the end of 2027.

## Funding rounds

- Series A, Jun 17, 2026, $46M — Canaan Partners, Alexandria Venture Investments, Westlake Village BioPartners

## Investors

- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Westlake Village BioPartners (https://capitalatlas.ai/funds/westlake-village-biopartners) — Series A